Preci
Precise Sciences (EXAS) got here out with a quarterly lack of $0.37 per share according to the Zacks Consensus Estimate. This compares to lack of $0.44 per share a 12 months in the past. These figures are adjusted for non-recurring objects.
1 / 4 in the past, it was anticipated that this molecular diagnostics firm would submit a lack of $0.41 per share when it really produced a lack of $0.31, delivering a shock of 24.39%.
During the last 4 quarters, the corporate has surpassed consensus EPS estimates two instances.
Precise Sciences, which belongs to the Zacks Medical – Biomedical and Genetics business, posted revenues of $295.58 million for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 0.40%. This compares to year-ago revenues of $142.98 million. The corporate has topped consensus income estimates 4 instances during the last 4 quarters.
The sustainability of the inventory’s quick worth motion based mostly on the recently-released…